CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Growth in prevalence of chronic conditions
3.4.1.2. Growth in awareness of health and screening programs
3.4.1.3. Surge in adoption of point of care testing
3.4.2. Restraints
3.4.2.1. Product recalls by top players
3.4.2.2. Lack of skilled personnel in underdeveloped countries
3.4.3. Opportunities
3.4.3.1. Technological advancements in hematological diagnostics instruments
CHAPTER 4: HEMATOLOGY DIAGNOSTICS MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Hematology Instrument
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Hematology Instrument Hematology Diagnostics Market by Type
4.2.4.1. Hematology Analyzers Hematology Diagnostics Market by Type
4.2.4.2. Flow Cytometry Hematology Diagnostics Market by Type
4.3. Hematology Consumables
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: HEMATOLOGY DIAGNOSTICS MARKET, BY TEST TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Complete Blood Count (CBC)
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Platelet Function Testing
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Hemoglobin Testing
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Others
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: HEMATOLOGY DIAGNOSTICS MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals and Clinics
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Diagnostic Laboratories
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Others
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: HEMATOLOGY DIAGNOSTICS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Product Type
7.2.3. Market size and forecast, by Test Type
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Product Type
7.2.5.1.2. Market size and forecast, by Test Type
7.2.5.1.3. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Product Type
7.2.5.2.2. Market size and forecast, by Test Type
7.2.5.2.3. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Product Type
7.2.5.3.2. Market size and forecast, by Test Type
7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Product Type
7.3.3. Market size and forecast, by Test Type
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Product Type
7.3.5.1.2. Market size and forecast, by Test Type
7.3.5.1.3. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Product Type
7.3.5.2.2. Market size and forecast, by Test Type
7.3.5.2.3. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Product Type
7.3.5.3.2. Market size and forecast, by Test Type
7.3.5.3.3. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Product Type
7.3.5.4.2. Market size and forecast, by Test Type
7.3.5.4.3. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Product Type
7.3.5.5.2. Market size and forecast, by Test Type
7.3.5.5.3. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Product Type
7.3.5.6.2. Market size and forecast, by Test Type
7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Product Type
7.4.3. Market size and forecast, by Test Type
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Product Type
7.4.5.1.2. Market size and forecast, by Test Type
7.4.5.1.3. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Product Type
7.4.5.2.2. Market size and forecast, by Test Type
7.4.5.2.3. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Product Type
7.4.5.3.2. Market size and forecast, by Test Type
7.4.5.3.3. Market size and forecast, by End User
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Product Type
7.4.5.4.2. Market size and forecast, by Test Type
7.4.5.4.3. Market size and forecast, by End User
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Product Type
7.4.5.5.2. Market size and forecast, by Test Type
7.4.5.5.3. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Product Type
7.4.5.6.2. Market size and forecast, by Test Type
7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Product Type
7.5.3. Market size and forecast, by Test Type
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Product Type
7.5.5.1.2. Market size and forecast, by Test Type
7.5.5.1.3. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Product Type
7.5.5.2.2. Market size and forecast, by Test Type
7.5.5.2.3. Market size and forecast, by End User
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Product Type
7.5.5.3.2. Market size and forecast, by Test Type
7.5.5.3.3. Market size and forecast, by End User
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Product Type
7.5.5.4.2. Market size and forecast, by Test Type
7.5.5.4.3. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Cardinal Health Inc.
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Danaher Corporation
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Siemens AG
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. F. Hoffmann-La Roche Ltd.
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Sysmex Corporation
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Abbott Laboratories
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. EKF Diagnostics Holdings plc
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Nihon Kohden Corporation
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Erba Mannheim
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
| ※参考情報 血液診断とは、血液を採取し、さまざまな検査を行って健康状態や病気の有無を確認する医療分野の一つです。血液は体の中で多くの貴重な情報を持っており、その成分や性質を分析することで、様々な疾患の早期発見や、治療効果の評価が可能となります。 血液診断の主な種類には、完全血球計算（CBC）、生化学的検査、免疫学的検査、 coagulation tests（凝固検査）などがあります。完全血球計算は、赤血球数、白血球数、血小板数といった血液成分の数を測定し、貧血、感染症、炎症、血液の疾患の有無を評価します。 生化学的検査では、血清中の糖、電解質、酵素などを測定します。これにより、糖尿病、腎疾患、肝疾患の診断が行われます。また、免疫学的検査は、ウイルス感染や自己免疫疾患の診断に用いられ、特定の抗体や抗原を測定します。因みに、感染症の早期発見には、特に感染性の病気に関連する抗体の有無を確認することが重要です。 凝固検査は、血液がどの程度凝固するかを測定するもので、出血傾向や血栓症のリスクを評価します。これには、PT（プロトロンビン時間）やAPTT（活性化部分トロンボプラスチン時間）などの指標が含まれ、血液が正常に凝固するために必要な因子の働きを示します。 血液診断の用途は多岐にわたります。定期検診や健康診断での健康状態のチェックだけでなく、特定の症状に基づく疾患の診断、治療のモニタリング、さらには特定の患者群に対するリスクアセスメントが行われます。また、移植医療やがん治療においても、患者の血液を検査することで治療方針を決定する際の重要なデータが得られます。 血液診断に関連する技術も進歩しています。自動化された血球計数機器の導入により、迅速かつ正確に血液成分の測定が行えるようになりました。また、分子生物学的技術の進展によって、特定の遺伝子変異や病原体の検出が可能となり、より精密な診断が実現しています。 さらに、最近では、ポイントオブケアテスト（POCT）という概念が進化を遂げています。これにより、医療機関外での迅速な血液検査が可能となり、患者の状態を迅速に把握することができます。この技術は、特に緊急時や遠隔地での医療提供において大いに役立っています。 血液診断は、今後も新たな技術革新が期待されている領域です。AIによるデータ分析や機械学習の導入が進み、診断精度の向上や迅速な治療判断が可能になる可能性が高まっています。これにより、患者の治療の質が向上し、医療の効率化が進むことが期待されています。 日常の健康管理において、血液診断は非常に重要な役割を果たしています。早期発見や早期治療に結びつく可能性が高いため、多くの人が定期的に血液検査を受けることが推奨されています。医療機関を訪れた際には、専門家のアドバイスをしっかりと受け、必要に応じて血液検査を実施していくことが、健康維持につながるでしょう。 血液診断は医療の基盤となる重要な要素であり、今後も技術革新と共に進化し続けるでしょう。これにより、患者の健康を守るために、より正確で迅速な診断が提供され、多くの疾患の早期発見が促進されることが期待されます。 |
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
